Developer docs
API playgroundTry for free, no card

Search company profiles

PolarityTE

Full company profile

uuid0005lkh

Namestring
PolarityTE
Legal namestring
PolarityTE, Inc.
Websiteurl
polarityte.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

PolarityTE, Inc., operating as PolarityBio, is a clinical-stage biotechnology company headquartered at 1960 South 4250 West, Salt Lake City, Utah, developing SkinTE, an investigational autologous cutaneous multicellular therapy designed to initiate the wound healing process in chronic wounds and diabetic foot ulcers. SkinTE is produced from a patient's own healthy tissue; the resulting multicellular units are applied to the wound bed, where the company states they may engraft and serve as a cellular source that drives tissue repair activity. The company's lead program targets Wagner Grade 1 diabetic foot ulcers and is currently in Phase III clinical development at up to 20 US clinical sites enrolling up to 120 subjects, with interim results previously targeted for Q1 2025. The technology platform is protected by a USPTO patent granted in February 2021, and the company also maintains an FDA-cleared Expanded Access Program that allows qualified providers to administer SkinTE to eligible patients outside of the trial setting.

The business is pre-commercial: SkinTE has not been approved or cleared by the FDA, and the company has no disclosed product pricing or recurring revenue. The go-to-market model relies on direct engagement with clinical sites and wound-care specialists, with a planned future commercial channel through hospital pharmacies, wound care centers, and specialty clinics contingent on regulatory approval. The company emerged from a 2023 bankruptcy filing, during which financing had been disrupted by an alleged short-and-distort scheme, and has since rebranded as PolarityBio and recapitalized. Headcount is reported at 11–50 employees, and the capital structure as of the available data is supported by approximately $35.5 million of disclosed funding across March 2022 ($5.0M registered direct), June 2022 ($8.0M securities offering), and May 2024 ($12.5M equity plus a $10M senior credit facility from Avenue Venture Opportunities Fund). The addressable market is meaningful — roughly 7 million US chronic wound cases in 2023 and a bioengineered skin market projected at $4.88 billion by 2030 at a 12.3% CAGR — but the company currently captures none of it.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSalt Lake City, United States
HQ citystring
Salt Lake City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative tissue therapy, wound healing biologics, autologous cell therapy, diabetic foot ulcer treatment, multicellular skin substitute
Industry3 codes
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAKACAN
Wound Care & Ulcer Management
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine Biologics
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1SkinTE (investigational product)
TypeOne Time License
Description

PolarityTE is a pre-commercial biotech company developing SkinTE, an autologous regenerative tissue product for chronic wound healing and diabetic foot ulcers. The company is in Phase III clinical trials with interim results expected Q1 2025. Revenue will be generated upon FDA approval through product sales to healthcare providers and hospitals.

globenewswire.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1SkinTE®
Description

Investigational autologous cutaneous multicellular therapy designed to initiate the wound healing process for chronic wounds and diabetic foot ulcers.

polaritybio.com
Core offering1 text field

PolarityTE/PolarityBio develops SkinTE, an investigational autologous cutaneous multicellular therapy designed to initiate the wound healing process by providing healthy cells and chemokines directly into the wound bed. The product is currently in Phase III clinical development for Wagner Grade 1 diabetic foot ulcers, supplemented by an FDA-cleared Expanded Access Program that provides eligible patients with investigational access.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

PolarityBio (formerly PolarityTE) is a biotechnology company developing SkinTE, an investigational autologous cutaneous multicellular biologic therapy. SkinTE is designed to initiate the wound healing process by providing healthy cells and chemokines in the wound bed for chronic wound healing and diabetic foot ulcers. The company operates through a single core product platform with clinical development programs advancing through Phase III trials, and maintains an FDA-cleared Expanded Access Program for eligible patients.

Product and service2 records
1SkinTE
CategoryRegenerative Medicine Biologic / Wound Healing Therapy
Description

SkinTE is an investigational, autologous cutaneous multicellular therapy designed to initiate the wound healing process by providing healthy cells and chemokines in the wound bed. Following application, multicellular units may engraft and serve as a cellular source within the wound bed, supporting tissue repair cellular activity. It is currently in Phase III clinical development for Wagner Grade 1 diabetic foot ulcers and is also available to eligible patients under an FDA-cleared Expanded Access Program.

2FDA-cleared Expanded Access Program for SkinTE
CategoryClinical Access Program / Investigational Therapy Access
Description

FDA-cleared program that enables selected healthcare providers to administer SkinTE to eligible patients with chronic wounds and diabetic foot ulcers prior to commercial approval, supporting investigational access and real-world data collection.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Organogenesis is the leading pure-play advanced wound care and regenerative medicine company, offering Apligraf and other skin substitutes for chronic wounds including diabetic foot ulcers and venous leg ulcers — directly competing with SkinTE in the same indication and customer base.

TypeBroad incumbent
Description

Smith+Nephew's Advanced Wound Management division offers a comprehensive portfolio including skin substitutes, negative pressure wound therapy, and dressings — competing broadly with SkinTE across the chronic wound care continuum.

TypeDirect peer
Description

MiMedx develops and commercializes amniotic membrane-based tissue grafts (e.g., EpiFix, AmnioFix) for chronic wound healing, including diabetic foot ulcers — a direct competitor to SkinTE in autologous/allogeneic regenerative wound therapy.

TypeBroad incumbent
Description

Coloplast's Wound & Skin Care business offers advanced wound dressings and skin care products for chronic wounds including diabetic foot ulcers — a broad incumbent serving the same end customer base as PolarityBio's target market.

TypeEmerging player
Description

Celularity develops placental-derived and cellular therapies for wound healing and regenerative medicine — an emerging player with biologically adjacent technology and overlapping target indications in chronic wound care.

TypeBroad incumbent
Description

3M's KCI division (formerly Acelity) is a market leader in advanced wound care with V.A.C. negative pressure wound therapy systems and skin substitute products — competing with SkinTE for hospital wound care budgets.

TypeBroad incumbent
Description

ConvaTec is a major global wound care company offering advanced dressings, negative pressure wound therapy, and skin substitutes for chronic wounds — competing with SkinTE for hospital and wound clinic accounts.

TypeBroad incumbent
Description

Integra LifeSciences offers Integra Dermal Regeneration Template and a broad wound care portfolio — a larger established incumbent with overlapping skin substitute and regenerative wound healing products competing with SkinTE.

9TissueTech
TypeEmerging player
Description

TissueTech develops and commercializes cryopreserved amniotic membrane and umbilical cord-based tissue grafts (e.g., AmnioGuard, Neox) for wound healing — an emerging competitor in regenerative wound care with overlapping indications to SkinTE.

TypeDirect peer
Description

Vericel develops autologous cellular therapies including MACI (cartilage repair) and Epicel (burns), using patient-derived cell technology — closely comparable to PolarityBio's autologous cutaneous multicellular therapy platform and regenerative medicine business model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PolarityTE

Regenerative Medicine Biologicspolarityte.com

What PolarityTE does

PolarityTE, Inc., operating as PolarityBio, is a clinical-stage biotechnology company headquartered at 1960 South 4250 West, Salt Lake City, Utah, developing SkinTE, an investigational autologous cutaneous multicellular therapy designed to initiate the wound healing process in chronic wounds and diabetic foot ulcers. SkinTE is produced from a patient's own healthy tissue; the resulting multicellular units are applied to the wound bed, where the company states they may engraft and serve as a cellular source that drives tissue repair activity. The company's lead program targets Wagner Grade 1 diabetic foot ulcers and is currently in Phase III clinical development at up to 20 US clinical sites enrolling up to 120 subjects, with interim results previously targeted for Q1 2025. The technology platform is protected by a USPTO patent granted in February 2021, and the company also maintains an FDA-cleared Expanded Access Program that allows qualified providers to administer SkinTE to eligible patients outside of the trial setting.

The business is pre-commercial: SkinTE has not been approved or cleared by the FDA, and the company has no disclosed product pricing or recurring revenue. The go-to-market model relies on direct engagement with clinical sites and wound-care specialists, with a planned future commercial channel through hospital pharmacies, wound care centers, and specialty clinics contingent on regulatory approval. The company emerged from a 2023 bankruptcy filing, during which financing had been disrupted by an alleged short-and-distort scheme, and has since rebranded as PolarityBio and recapitalized. Headcount is reported at 11–50 employees, and the capital structure as of the available data is supported by approximately $35.5 million of disclosed funding across March 2022 ($5.0M registered direct), June 2022 ($8.0M securities offering), and May 2024 ($12.5M equity plus a $10M senior credit facility from Avenue Venture Opportunities Fund). The addressable market is meaningful — roughly 7 million US chronic wound cases in 2023 and a bioengineered skin market projected at $4.88 billion by 2030 at a 12.3% CAGR — but the company currently captures none of it.

PolarityTE firmographics

Firmographics
Name
PolarityTE
Legal name
PolarityTE, Inc.
Website
https://polarityte.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

PolarityTE industry classification

Industry
Product category
Regenerative Medicine Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAKACAN
Wound Care & Ulcer Management

Keywords

  • Regenerative tissue therapy
  • Wound healing biologics
  • Autologous cell therapy
  • Diabetic foot ulcer treatment
  • Multicellular skin substitute

Where PolarityTE is headquartered

Location

Headquarters

HQ city
Salt Lake City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

PolarityTE business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Others

Revenue model

  1. SkinTE (investigational product): PolarityTE is a pre-commercial biotech company developing SkinTE, an autologous regenerative tissue product for chronic wound healing and diabetic foot ulcers. The company is in Phase III clinical trials with interim results expected Q1 2025. Revenue will be generated upon FDA approval through product sales to healthcare providers and hospitals.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

PolarityTE product offering

Product offering

Core offering

PolarityTE/PolarityBio develops SkinTE, an investigational autologous cutaneous multicellular therapy designed to initiate the wound healing process by providing healthy cells and chemokines directly into the wound bed. The product is currently in Phase III clinical development for Wagner Grade 1 diabetic foot ulcers, supplemented by an FDA-cleared Expanded Access Program that provides eligible patients with investigational access.

Product overview

PolarityBio (formerly PolarityTE) is a biotechnology company developing SkinTE, an investigational autologous cutaneous multicellular biologic therapy. SkinTE is designed to initiate the wound healing process by providing healthy cells and chemokines in the wound bed for chronic wound healing and diabetic foot ulcers. The company operates through a single core product platform with clinical development programs advancing through Phase III trials, and maintains an FDA-cleared Expanded Access Program for eligible patients.

Differentiator

Problem solved

Functional benefit

Brands

  • SkinTE®: Investigational autologous cutaneous multicellular therapy designed to initiate the wound healing process for chronic wounds and diabetic foot ulcers.

Products and services

  • SkinTE SkinTE is an investigational, autologous cutaneous multicellular therapy designed to initiate the wound healing process by providing healthy cells and chemokines in the wound bed. Following application, multicellular units may engraft and serve as a cellular source within the wound bed, supporting tissue repair cellular activity. It is currently in Phase III clinical development for Wagner Grade 1 diabetic foot ulcers and is also available to eligible patients under an FDA-cleared Expanded Access Program.
  • FDA-cleared Expanded Access Program for SkinTE FDA-cleared program that enables selected healthcare providers to administer SkinTE to eligible patients with chronic wounds and diabetic foot ulcers prior to commercial approval, supporting investigational access and real-world data collection.

Companies that use PolarityTE

Customer profile

Segments1 record

Ideal customer profiles1 record

PolarityTE technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

PolarityTE partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

PolarityTE competitors and assessment

Company assessment

Direct peers

  • Organogenesis Holdings: Organogenesis is the leading pure-play advanced wound care and regenerative medicine company, offering Apligraf and other skin substitutes for chronic wounds including diabetic foot ulcers and venous leg ulcers — directly competing with SkinTE in the same indication and customer base.
  • MiMedx Group: MiMedx develops and commercializes amniotic membrane-based tissue grafts (e.g., EpiFix, AmnioFix) for chronic wound healing, including diabetic foot ulcers — a direct competitor to SkinTE in autologous/allogeneic regenerative wound therapy.
  • Vericel Corporation: Vericel develops autologous cellular therapies including MACI (cartilage repair) and Epicel (burns), using patient-derived cell technology — closely comparable to PolarityBio's autologous cutaneous multicellular therapy platform and regenerative medicine business model.

Broad incumbents

  • Smith+Nephew: Smith+Nephew's Advanced Wound Management division offers a comprehensive portfolio including skin substitutes, negative pressure wound therapy, and dressings — competing broadly with SkinTE across the chronic wound care continuum.
  • Coloplast: Coloplast's Wound & Skin Care business offers advanced wound dressings and skin care products for chronic wounds including diabetic foot ulcers — a broad incumbent serving the same end customer base as PolarityBio's target market.
  • 3M Health Care (KCI): 3M's KCI division (formerly Acelity) is a market leader in advanced wound care with V.A.C. negative pressure wound therapy systems and skin substitute products — competing with SkinTE for hospital wound care budgets.
  • ConvaTec Group: ConvaTec is a major global wound care company offering advanced dressings, negative pressure wound therapy, and skin substitutes for chronic wounds — competing with SkinTE for hospital and wound clinic accounts.
  • Integra LifeSciences: Integra LifeSciences offers Integra Dermal Regeneration Template and a broad wound care portfolio — a larger established incumbent with overlapping skin substitute and regenerative wound healing products competing with SkinTE.

Emerging players

  • Celularity: Celularity develops placental-derived and cellular therapies for wound healing and regenerative medicine — an emerging player with biologically adjacent technology and overlapping target indications in chronic wound care.
  • TissueTech: TissueTech develops and commercializes cryopreserved amniotic membrane and umbilical cord-based tissue grafts (e.g., AmnioGuard, Neox) for wound healing — an emerging competitor in regenerative wound care with overlapping indications to SkinTE.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

PolarityTE social profiles

Digital presence

PolarityTE financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PolarityTE leadership team

Management profile

Number of profiles

Profiles11 records

PolarityTE funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PolarityTE M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PolarityTE

What does PolarityTE do?

PolarityTE/PolarityBio develops SkinTE, an investigational autologous cutaneous multicellular therapy designed to initiate the wound healing process by providing healthy cells and chemokines directly into the wound bed. The product is currently in Phase III clinical development for Wagner Grade 1 diabetic foot ulcers, supplemented by an FDA-cleared Expanded Access Program that provides eligible patients with investigational access.

Is PolarityTE a public or private company?

PolarityTE is a private company. It is classified as unknown and is currently operating.

When was PolarityTE founded?

PolarityTE was founded in 1998. It employs 11 to 50 people.

Where is PolarityTE based?

PolarityTE is headquartered in Salt Lake City, United States, in the North America region.

How does PolarityTE make money?

One revenue line is on record: skinTE (investigational product).

Who are PolarityTE's main competitors?

Direct peers on record are Organogenesis Holdings, MiMedx Group and Vericel Corporation. Broad incumbents are Smith+Nephew, Coloplast, 3M Health Care (KCI), ConvaTec Group and Integra LifeSciences. Emerging players are Celularity and TissueTech.

Does PolarityTE have an API?

No public API is recorded for PolarityTE.

What industry is PolarityTE in?

PolarityTE's product category is Regenerative Medicine Biologics. Its primary akta.pro industry code is HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes), with a secondary code of HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialChronic Wounds - Drug Pipeline Analysis, Emerging Therapies, And Competitive Landscape, 2026 Phase III Programs And Advanced Wound Care Innovation Drive Strategic OpportunitiesResearchAndMarkets.com released a report analyzing the chronic wounds drug pipeline, covering over 30 companies and 30+ investigational products. It highlights SkinTE from PolarityTE in Phase III development, along with candidates from Aurealis Therapeutics and Akribes Biomedical. The report assesses development phases, routes of administration, and competitive landscape.TechBullionThe Gone Girl of Wall Street: How a False Story Destroyed a Real Investor & TruthBarry Honig, an investor publicly vilified by Citron Research reports starting in 2018, has been vindicated after a July 2024 DOJ indictment charged Andrew Left with a $16-20 million securities fraud scheme involving 21-23 targeted companies. The SEC confirmed that Anson Funds Management secretly paid Left via shell company Falcon Research to publish stock attacks on companies they were already shorting, destroying innocent shareholders—including Honig who held nearly 10% of PolarityTE. PolarityTE's patent, which Citron declared "dead on arrival" in 2018, was actually granted by the USPTO in February 2021, and in May 2026 Honig filed a civil lawsuit in Dallas federal court against Anson Funds, Moez Kassam, Sunny Puri, and Ryan Choi.TechBullionThe Government Proved It Was a Scheme. Barry Honig Was a Victim.In June 2024, the SEC charged Anson Funds Management, a $2.9 billion hedge fund, with running a coordinated short-and-distort scheme from 2018 to 2023, where the fund secretly paid Andrew Left of Citron Research to publish false negative reports about targeted companies to drive their stocks down. One victim was PolarityTE, a biotech company whose stock crashed over 40% after Citron published a false 'FRAUD' report claiming its patent had been rejected—claims that were later proven wrong when the USPTO granted the patent in 2021, but the company had already lost financing and declared bankruptcy in 2023. Andrew Left was subsequently indicted by the DOJ in July 2024 on 19 criminal counts including securities fraud, facing up to 365 years in prison, with his trial scheduled for 2026.openPR.comChronic Wounds Market: Accelerating Growth and Pipeline Impact by 2034 - DelveInsight | Paracrine, Inc, Oneness Biotech, MediWound, PolarityTEDelveInsight published a market insights report projecting the chronic wounds market to grow significantly through 2034, with the US market reporting approximately 7 million chronic wound cases in 2023 across pressure ulcers (38%), diabetic foot ulcers (35%), venous ulcers (18%), and other types. Multiple companies are advancing pipeline products through clinical trials, including Rapid Nexus Nanotech Wound Solutions receiving FDA 510(k) clearance for Hemastyl gel (November 2025), MediWound advancing its Phase III EscharEx candidate for chronic wound debridement, and SolasCure initiating the CLEANVLU2 Phase II trial for its Aurase Wound Gel (March 2025).FinSMEsPolarityTE Raises $22.5M FinancingPolarityTE, a clinical-stage biotechnology company based in Salt Lake City, UT, raised $22.5 million in funding from institutional investors and shareholders. The funds will be used to advance the Phase III Pivotal Study for SkinTE, targeting treatment for Wagner 1 Diabetic Foot Ulcers. Additionally, the company secured a credit facility with Avenue Capital Group providing up to $10 million in term loan capital.MorningstarPolarityTE Secures $22.5 Million Financing to Advance SkinTE Phase III Pivotal Study in Diabetic Foot UlcersPolarityTE raised $12.5 million in equity and secured a $10 million credit facility from Avenue Venture Debt Fund. The funds will advance its Phase III pivotal study for SkinTE in diabetic foot ulcers, which has enrolled about 20% of its target population.BioSpacePolarityTE Secures $22.5 Million Financing to Advance SkinTE Phase III Pivotal Study in Diabetic Foot UlcersPolarityTE secured $22.5 million in combined equity and debt financing to advance the Phase III pivotal study of SkinTE for treating diabetic foot ulcers. The capital raise includes $12.5 million from investors and a new senior secured credit facility with Avenue Capital Group, providing sufficient funds to reach key data readouts expected in Q1 2025. The COVER DFUS II trial is currently enrolling subjects at clinical sites across the United States.GlobeNewswirePolarityTE Secures $22.5 Million Financing to Advance SkinTE Phase III Pivotal Study in Diabetic Foot UlcersPolarityTE secured $12.5 million in equity financing and a new senior secured credit facility with Avenue Capital Group to fund its operations. The proceeds will advance the Phase III COVER DFUS II pivotal study for SkinTE, a regenerative tissue product used to treat diabetic foot ulcers. The trial aims to enroll 120 subjects across 20 sites in the United States, with an interim data readout expected in Q1 2025.GlobeNewswirePolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot UlcersPolarityTE announced the first subject screened in its Phase III pivotal study evaluating SkinTE for Wagner grade 1 diabetic foot ulcers. The COVER DFUS II trial will enroll up to 120 subjects at 20 U.S. sites, randomizing them to SkinTE plus standard of care or standard of care alone, with the primary endpoint being ulcer closure at 12 weeks.BioSpacePolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot UlcersPolarityTE announced the screening of the first subject in its Phase III pivotal study, COVER DFUS II, evaluating the investigational drug SkinTE for treating Wagner grade 1 diabetic foot ulcers. The trial will enroll up to 120 subjects across 20 clinical sites in the United States to assess the efficacy of SkinTE combined with standard of care versus standard of care alone. This milestone is a critical step for PolarityTE as it pursues regulatory approval via a biologics license application.